Atara Biotherapeutics, Inc.
2659 Townsgate Road
Suite 236
Thousand Oaks
California
91361
United States
208 articles with Atara Biotherapeutics, Inc.
-
Bayer has terminated a two year-old partnership with Atara to develop off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
-
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
5/19/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it received notification of Bayer’s intention to end the exclusive worldwide licensing agreement for next-generation mesothelin-directed CAR T-cell therapies.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 06, 2022
5/6/2022
Atara Biotherapeutics, Inc. reported the grant of an aggregate of 115,059 restricted stock units of Atara’s common stock to 13 newly hired employees and stock options to purchase an aggregate of 118,745 shares of Atara’s common stock to eight such newly hired employees.
-
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
5/5/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2022, recent business highlights and key upcoming catalysts.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 29, 2022
4/29/2022
Atara Biotherapeutics, Inc. reported the grant of inducement awards to Charlene Banard, its new Executive Vice President, Chief Technical Officer.
-
Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
4/28/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release first quarter 2022 financial results after market close on Thursday, May 5, 2022.
-
Patient deaths associated with Astellas Pharma’s gene therapy candidate underscore the risks of developing potential one-and-done treatment options for serious diseases.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 22, 2022
4/22/2022
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of inducement awards to Brian Robinson, its new Senior Vice President, Global Medical Affairs.
-
There are an estimated 2.3 million people living with Multiple Sclerosis and hundreds of thousands more undiagnosed, adding up to an annual cost of nearly $85 billion for care in the United States.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 08, 2022
4/8/2022
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 37,538 restricted stock units of Atara’s common stock to five newly hired employees.
-
Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
4/5/2022
Atara Biotherapeutics, Inc. today announces biopharmaceutical executive Charlene Banard will join as Chief Technical Officer.
-
Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
4/4/2022
Atara Biotherapeutics, Inc. today announced FUJIFILM Diosynth Biotechnologies has completed the acquisition of Atara’s cell therapy manufacturing facility in Thousand Oaks.
-
Atara Biotherapeutics to Host EBV and MS Day
3/15/2022
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, will host an EBV and multiple sclerosis Day on Tuesday, March 22, 2022 from 4:00 – 6:00 p.m. EDT.
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Mar 04, 2022
3/4/2022
Atara Biotherapeutics, Inc. reported the grant of an aggregate of 45,040 restricted stock units of Atara’s common stock to nine newly hired employees and stock options to purchase an aggregate of 39,978 shares of Atara’s common stock to three such newly hired employees.
-
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
2/28/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2021, recent business highlights and key upcoming catalysts for 2022.
-
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
2/18/2022
Atara Biotherapeutics, Inc. today reported Memorial Sloan Kettering Cancer Center’s (MSK) notification to the U.S. Food and Drug Administration (FDA) of a fatal serious adverse event (SAE) associated with a patient treated in the ongoing Phase 1 MSK-conducted dose-escalation clinical study of autologous mesothelin CAR T, ATA2271.
-
Patient enrollment for the clinical trial, which was testing Atara’s autologous chimeric antigen receptor (CAR) T-cell immunology therapy called ATA2271, has been paused.
-
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
2/17/2022
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2021 financial results after market close on Monday, February 28, 2022.
-
The fund will be used to target partnerships with promising early-stage biotechnology to enhance Fujifilm's life sciences portfolio.